No Biological Evidence of XMRV Infection in Cervical Smears from HIV/ HPV Positive and Negative Kenyan Women

BACKGROUND: XMRV (xenotropic murine leukaemia virus-related virus) is a gammaretrovirus first discovered in human prostate carcinomas and later linked to chronic fatigue syndrome (CFS). Emerging conflicting data and lack of reproducibility of results within the scientific community has now led to the association of XMRV with CFS being discounted. Indeed the case for an involvement with any human disease has been questioned with the suggestion that XMRV is a laboratory generated recombinant virus. The fact that not all published positive findings can be easily explained as contamination artefacts coupled with the observation that XMRV may have a sexually transmitted mode of infectivity and can be infectious for primates, where it preferential resides in cells of the reproductive tract, prompted us to look for evidence of XMRV in the cervical cells of a cohort of Kenyan women both with and without pre-existing HIV/HPV infections. RESULTS: Using a highly sensitive and selective triplex PCR approach we analysed DNA from the liquid based cytology (LBC) cervical smears of 224 Kenyan women. There was no evidence of XMRV expression in any of the sample population irrespective of HPV and/or HIV status. CONCLUSIONS: The data presented show no indication of XMRV infection in any of the cervical samples screened in this study. Approximately 50% of the women were HIV positive but this did not influence the findings signifying that XMRV does not act as an opportunistic infection in this cohort nor is it related to HPV status. Our results therefore support the findings that XMRV is confined to the laboratory and does not currently represent an infectious agent for humans, with a cautionary adage that such potential zoonotic viruses should be carefully monitored in the future

Sedimentology and kinematics of a large, retrogressive growth-fault system in Upper Carboniferous deltaic sediments, western Ireland

Growth faulting is a common feature of many deltaic environments and is vital in determining local sediment dispersal and accumulation, and hence in controlling the resultant sedimentary facies distribution and architecture. Growth faults occur on a range of scales, from a few centimetres to hundreds of metres, with the largest growth faults frequently being under-represented in outcrops that are often smaller than the scale of feature under investigation. This paper presents data from the exceptionally large outcrops of the Cliffs of Moher, western Ireland, where a growth-fault complex affects strata up to 60 m in thickness and extends laterally for 3 km. Study of this Namurian (Upper Carboniferous) growth-fault system enables the relationship between growth faulting and sedimentation to be detailed and permits reconstruction of the kinematic history of faulting. Growth faulting was initiated with the onset of sandstone deposition on a succession of silty mudstones that overlie a thin, marine shale. The decollement horizon developed at the top of the marine shale contact for the first nine faults, by which time aggradation in the hangingwall exceeded 60 m in thickness. After this time, failure planes developed at higher stratigraphic levels and were associated with smaller scale faults. The fault complex shows a dominantly landward retrogressive movement, in which only one fault was largely active at any one time. There is no evidence of compressional features at the base of the growth faults, thus suggesting open-ended slides, and the faults display both disintegrative and non-disintegrative structure. Thin-bedded, distal mouth bar facies dominate the hangingwall stratigraphy and, in the final stages of growth-fault movement, erosion of the crests of rollover structures resulted in the highest strata being restricted to the proximity of the fault. These upper erosion surfaces on the fault scarp developed erosive chutes that were cut parallel to flow and are downlapped by the distal hangingwall strata of younger growth faults

Chemical kinetics and photochemical data for use in stratospheric modeling

Rate constants and photochemical cross sections are presented. The primary application of the data is for modeling of the stratospheric processes, with particular emphasis on the ozone layer and its possible perturbation by anthropogenic and natural phenomena

Chemical kinetics and photochemical data for use in stratospheric modeling. Evaluation number 6

Evaluated sets of rate constants and photochemical cross sections are presented. The primary application of the data is in the modeling of stratospheric processes, with particular emphasis on the ozone layer and its possible perturbation by anthropogenic and natural phenomena

Chemical kinetics and photochemical data for use in stratospheric modeling evaluation Number 8

This is the eighth in a series of evaluated sets of rate constants and photochemical cross sections compiled by the NASA Panel for Data Evaluation. The primary application of the data is in the modeling of stratospheric processes, with particular emphasis on the ozone layer and its possible perturbation by anthropogenic and natural phenomena. Copies of this evaluation are available from the Jet Propulsion Laboratory, Documentation Section, 111-116B, California Institute of Technology, Pasadena, California, 91109

Chemical kinetics and photochemical data for use in stratospheric modeling

As part of a series of evaluated sets, rate constants and photochemical cross sections compiled by the NASA Panel for Data Evaluation are provided. The primary application of the data is in the modeling of stratospheric processes, with particular emphasis on the ozone layer and its possible perturbation by anthropogenic and natural phenomena. Copies of this evaluation are available from the Jet Propulsion Laboratory

Costs analysis of a population level rabies control programme in Tamil Nadu, India

The study aimed to determine costs to the state government of implementing different interventions for controlling rabies among the entire human and animal populations of Tamil Nadu. This built upon an earlier assessment of Tamil Nadu’s efforts to control rabies. Anti-rabies vaccines were made available at all health facilities. Costs were estimated for five different combinations of animal and human interventions using an activity-based costing approach from the provider perspective. Disease and population data were sourced from the state surveillance data, human census and livestock census. Program costs were extrapolated from official documents. All capital costs were depreciated to estimate annualized costs. All costs were inflated to 2012 Rupees. Sensitivity analysis was conducted across all major cost centres to assess their relative impact on program costs. It was found that the annual costs of providing Anti-rabies vaccine alone and in combination with Immunoglobulins was \$0.7 million (Rs 36 million) and \$2.2 million (Rs 119 million), respectively. For animal sector interventions, the annualised costs of rolling out surgical sterilisation-immunization, injectable immunization and oral immunizations were estimated to be \$ 44 million (Rs 2,350 million), \$23 million (Rs 1,230 million) and \$ 11 million (Rs 590 million), respectively. Dog bite incidence, health systems coverage and cost of rabies biologicals were found to be important drivers of costs for human interventions. For the animal sector interventions, the size of dog catching team, dog population and vaccine costs were found to be driving the costs. Rabies control in Tamil Nadu seems a costly proposition the way it is currently structured. Policy makers in Tamil Nadu and other similar settings should consider the long-term financial sustainability before embarking upon a state or nation-wide rabies control programme

The translation of cell-based therapies:clinical landscape and manufacturing challenges

Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development

Predictable patterns in stacking and distribution of channelized fluvial sand bodies linked to channel mobility and avulsion processes

ACKNOWLEDGMENTS Funding from the American Chemical Society Petroleum Research Fund (ACS PRF 50310-DNI8), the University of New Orleans (Louisiana, USA), and a Marie Skłodowska-Curie grant (no. 707404) is thankfully acknowledged. We thank Martin Gibling, Mike Blum, and Jeffrey Nittrouer for constructive and critical reviews.Peer reviewedPublisher PD